JWH-133

JWH-133 is a potent selective CB₂ receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB₂ over CB₁ receptors. It was discovered by and named after, John W. Huffman.

JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers . This anti-inflammatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.

Legal Status

The substance commonly referred to as "JWH-133" is not a scheduled substance in the U.S, except in Alabama. Low abuse potential makes it less likely for regulation relative to its sister drugs such as JWH-018, as JWH-133 is selective for the non-psychoactive CB₂ receptor and thus lacks significant psychoactive effects.

JWH-176

JWH-176 is an analgesic drug which acts as a cannabinoid receptor agonist. Its binding affinity at the CB₁ receptor is only 26.0nM, making it more potent than THC itself, however JWH-176 is particularly notable in that it is a hydrocarbon containing no heteroatoms. This demonstrates that reasonably high-affinity cannabinoid binding and agonist effects can be produced by compounds with no hydrogen bonding capacity at all, relying merely on Van der Waals interactions to bind to the receptor. It was discovered by, and named after, Dr. John W. Huffman.

See also

References

JWH-398

JWH-398 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB₁ and CB₂ receptors. It has mild selectivity for CB₁ with a K_i of 2.3nM and 2.8nM at CB₂. It was identified by the EMCDDA as an ingredient in three separate "herbal incense" products purchased from online shops between February to June 2009. It was discovered by, and named after, Dr. John W. Huffman.

See also

References

JWH-019

JWH-019 is an analgesic chemical from the naphthoylindole family that acts as a cannabinoid agonist at both the CB₁ and CB₂ receptors. It is the N1-hexyl homologue of the more common synthetic cannabinoid compound JWH-018. Unlike the butyl homologue JWH-073, which is several times weaker than JWH-018, the hexyl homologue is only slightly less potent, although extending the chain one carbon longer to the heptyl homologue JWH-020 results in dramatic loss of activity. These results show that the optimum side chain length for CB₁ binding in the naphthoylindole series is the five-carbon pentyl chain, shorter than in the classical cannabinoids where a seven-carbon heptyl chain produces the most potent compounds. This difference is thought to reflect a slightly different binding conformation adopted by the naphthoylindole compounds as compared to the classical cannabinoids, and may be useful in characterising the active site of the CB₁ and CB₂ receptors.

Legal Status

China

As of October 2015 JWH-019 is a controlled substance in China.